Latest newsClassic list
Globally incubate standards compliant channels before scalable benefits. Quickly disseminate superior deliverables whereas web-enabled applications.Latest newsNews
Credibly innovate granular internal or “organic“ sources whereas high standards in web-readiness. Energistically scale future-proof core competencies.
Prof. Moses Joloba was recognized by CDC Global for his effort to fight tuberculosis in Africa in the year 2022. Prof. Moses Joloba, Director of Uganda’s Nat’l. TB Reference Laboratory, has built capacity for #TB diagnosis & surveillance for 25+ years. His leadership was vital in the GeneXpert platform expansion, which helps diagnose drug resistant TB.
It is with great pleasure that I present to you the second Annual Report of the Makerere University Biomedical Research Centre (MakBRC), which captures our performance for the year 2021- 2022. The Centre is committed to demonstrating integrated thinking and value creation for our stakeholders, as well as sustainability for the future as we work towards championing biomedical sciences.
The MakBRC Board of Directors remains committed to providing an enabling corporate governance framework and supporting the company to achieve its five-year strategic plan.
I take this opportunity to reassure our stakeholders that the MakBRC is a center of sound repute, premised to build on its achievements. Our highly experienced leadership coupled with a competent team of staff members will always strive to deliver exceptional performance against the set targets.
On behalf of the Board of Directors, I thank all our stakeholders for supporting the organization. I equally thank the management and staff for innovatively transforming the company to what it is today.
Prof. William Buwembo
CHAIRMAN BOARD OF DIRECTORS
Nabukenya, S., Waitt, C., Senyonga, R., Castelnuovo, B., Munabi, I. G., Kyaddondo, D., & Mwaka, E. S. (2023). Research participants’ preferences for individual results of pharmacogenomics research: A Case of a Ugandan HIV Research Institute. Journal of Empirical Research on Human Research Ethics, 18(4), 218-232.
Mijumbi, A. O., Mugenyi, L., Nanfuka, M., Agaba, C., & Ochieng, J. (2023). Regulation of community advisory boards during conduct of clinical trials in Uganda: a qualitative study involving stakeholders. BMC Health Services Research, 23(1), 119.
We are extending the deadline for the Post-Doctoral Research Fellow in Immunology and Tissue Biology (AHRI Durban Campus) – we would be grateful if you could disseminate this information widely within your networks – (details below):
Description:
This three-year postdoctoral position in Professor Zaza Ndhlovu’s research group at AHRI in Durban, South Africa, is embedded in a recently awarded Bill and Melinda Gates-funded grant.
The major barrier to HIV prevention and cure efforts is the extremely rapid establishment of reservoirs throughout the body. The precise nature, phenotype, and size of the persistent HIV reservoirs in tissues is poorly understood. The project will involve studying human tissue samples that are highly enriched in lymphoid structures such as lymph nodes, gut and various post-mortem samples. The tissues will be analyzed using the best-in class spatial imaging technology to defining where HIV hides within the human body during therapy and examine how persistent infection alters tissue resident immunity. Knowledge gained from this study will be used to design a cure for HIV which entails total eradication of HIV from the body.
This project is part of the BMGF funded international HIV reservoirs consortium that brings together experts in high dimensional imaging, human immunology, virology, and HIV vaccinology. The project will therefore involve regular interactions with this extensive international research network and is an excellent opportunity for a rapid career development.
Requirements
How to apply
Please send a cover letter and C.V with the subject listed as ‘Postdoc in Immunology and tissue biology, ZN’ to education@ahri.org. The closing date for applications is 28 February 2023.
